Topiramate selectively decreases intracortical excitability in human motor cortex

Epilepsia

Volumn 43, Issue 10, 2002, Pages 1149-1156

  Reis, Janine ^a   Tergau, Frithjof ^b   Hamer, Hajo M ^a   Müller, Hans Helge ^a   Knake, Susanne ^a   Fritsch, Brita ^a   Oertel, Wolfgang H ^a   Rosenow, Felix ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Antiepileptic drug; GABA; Glutamate; Human motor cortex; Intracortical facilitation; Intracortical inhibition; Ion channels; Topiramate; Transcranial magnetic stimulation

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; ION CHANNEL; TOPIRAMATE;

ADULT; ARTICLE; ATAXIA; BRADYKINESIA; BRAIN ELECTROPHYSIOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; GABAERGIC TRANSMISSION; HUMAN; MALE; MENTAL DEFICIENCY; MOTOR CORTEX; NERVE EXCITABILITY; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TASTE DISORDER; TRANSCRANIAL MAGNETIC STIMULATION; VERTIGO;

ADULT; BRAIN; ELECTROMYOGRAPHY; EPILEPSY; EVOKED POTENTIALS, MOTOR; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FRUCTOSE; GABA AGONISTS; HUMANS; ION CHANNELS; MAGNETICS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MOTOR CORTEX; NEURAL INHIBITION; PLACEBOS;

EID: 0036796126     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2002.09902.x     Document Type: Article

References (46)

1. Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996;24:73-7.
2. White HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997;38(suppl 1):S9-17.
3. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures: Topiramate YTC Study Group. Neurology 1999;52:1330-7.
4. Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000;41:977-80.
5. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(suppl 1):S3-9.
6. McLean MJ, Bukhari AA, Wamil AW. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2000;41(suppl 1):S214-4.
7. Wu SP, Tsai JJ, Gean PW. Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices. Br J Pharmacol 1998;125:826-32.
8. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997;231:123-6.
9. Brown SD, Wolf HH, Swinyard EA, et al. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993;34(suppl 2):122-3.
10. White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;28:167-79.
11. Gibbs JW III, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000;41(suppl 1):S10-6.
12. White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000;41(suppl 1):S17-20.
13. Zhang X, Velumian AA, Jones OT, et al. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2000;41(suppl 1):S52-60.
14. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia 1994;35:450-60.
15. Kuzniecky R, Hetherington H, Ho S, et al. Topiramate increases cerebral GABA in healthy humans. Neurology 1998;51:627-9.
16. Kuzniecky R, Ho S, Pan J, et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002;58:368-72.
17. Petroff OA, Hyder F, Rothman DL, et al. Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia 2001;42:543-8.
18. Manganotti P, Bongiovanni LG, Zanette G, et al. Cortical excitability in patients after loading doses of lamotrigine: a study with magnetic brain stimulation. Epilepsia 1999;40:316-21.
19. Ziemann U, Rothwell JC, Ridding MC. Interaction between intracortical inhibition and facilitation in human motor cortex. J Physiol 1996;496:873-81.
20. Siebner HR, Dressnandt J, Auer C, et al. Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 1998;21:1209-12.
21. Manganotti P, Bongiovanni LG, Zanette G, et al. Early and late intracortical inhibition in juvenile myoclonic epilepsy. Epilepsia 2000;41:1129-38.
22. Schwenkreis P, Liepert J, Witscher K, et al. Riluzole suppresses motor cortex facilitation in correlation to its plasma level: a study using transcranial magnetic stimulation. Exp Brain Res 2000;135:293-9.
23. Ziemann U, Chen R, Cohen LG, et al. Dextromethorphan decreases the excitability of the human motor cortex. Neurology 1998;51:1320-4.
24. Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. J Physiol 1993;471:501-19.
25. Mills KR, Boniface SJ, Schubert M. Magnetic brain stimulation with a double coil: the importance of coil orientation. Electroencephalogr Clin Neurophysiol 1992;85:17-21.
26. Werhahn KJ, Kunesch E, Noachtar S, et al. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 1999;517:591-7.
27. Tergau F, Wanschura V, Canelo M, et al. Complete suppression of voluntary motor drive during the silent period after transcranial magnetic stimulation. Exp Brain Res 1999;124:447-54.
28. Wilson SA, Lockwood RJ, Thickbroom GW, et al. The muscle silent period following transcranial magnetic cortical stimulation. J Neurol Sci 1993;114:216-22.
29. Garvey MA, Ziemann U, Becker DA, et al. New graphical method to measure silent periods evoked by transcranial magnetic stimulation. Clin Neurophysiol 2001;112:1451-60.
30. Ben-Menachem E. Potential antiepileptic drugs. In: Levy RH, ed. Topiramate: antiepileptic drugs. New York: Raven Press, 1995:1063-70.
31. Walker MC, Sander JW. Topiramate: a new antiepileptic drug for refractory epilepsy. Seizure 1996;5:199-203.
32. Christensen J, Hojskov CS, Dam M, et al. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit 2001;23:529-35.
33. Ziemann U, Lonnecker S, Steinhoff BJ, et al. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996;40:367-78.
34. Ziemann U, Lonnecker S, Steinhoff BJ, et al. The effect of lorazepam on the motor cortical excitability in man. Exp Brain Res 1996;109:127-35.
35. Schwenkreis P, Witscher K, Janssen F, et al. Influence of the N-methyl-D-aspartate antagonist memantine on human motor cortex excitability. Neurosci Lett 1999;270:137-40.
36. Hess CW, Mills KR, Murray NM, et al. Excitability of the human motor cortex is enhanced during REM sleep. Neurosci Lett 1987;82:47-52.
37. Chen R, Samii A, Canos M, et al. Effects of phenytoin on cortical excitability in humans. Neurology 1997;49:881-3.
38. Hallett M. Transcranial magnetic stimulation: negative effects. Adv Neurol 1995;67:107-13.
39. Roick H, von Giesen HJ, Benecke R. On the origin of the postexcitatory inhibition seen after transcranial magnetic brain stimulation in awake human subjects. Exp Brain Res 1993;94:489-98.
40. Sills GJ, Leach JP, Kilpatrick WS, et al. Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt. Epilepsia 2000;41:30-4.
41. Berkovic SF. Aggravation of generalized epilepsies. Epilepsia 1998;39(suppl 3):S11-4.
42. Hosford DA, Wang Y. Utility of the lethargic (1h/1h) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997;38:408-14.
43. Wheless JW. Use of topiramate in childhood generalized seizure disorders. J Child Neurol 2000;15(suppl 1):S7-13.
44. Knake S, Hamer HM, Schomburg U, et al. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure 1999;8:314-7.
45. Eckardt KM, Steinhoff BJ. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia 1998;39:671-4.
46. Boroojerdi B, Kopylev L, Battaglia F, et al. Reproducibility of intracortical inhibition and facilitation using the paired-pulse paradigm. Muscle Nerve 2000;23:1594-7.